Cargando…
Sustained release of brimonidine from BRI@SR@TPU implant for treatment of glaucoma
Glaucoma is the leading cause of irreversible vision loss worldwide, and reduction of intraocular pressure (IOP) is the only factor that can be interfered to delay disease progression. As the first line and preferred method to treat glaucoma, eye drops have many shortcomings, such as low bioavailabi...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8856066/ https://www.ncbi.nlm.nih.gov/pubmed/35174743 http://dx.doi.org/10.1080/10717544.2022.2039806 |